You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
醫藥股普遍捱沽 和鉑、康方及雲頂新耀續挫近7.5%-14% 惟北京健康升逾1倍
恆指維持於今早所造低位21,085之上爭持,現報21,152,續挫508點或2.3%,總成交額1,012億元。 俗稱「B仔股」生物科技企業股今天沽壓沉重,跌幅普遍超過大市,尤其是雲頂新耀-B(01952.HK)兩連跌,股價承上周五失守10天後,今天進一步跌破20天線(23.6元),現報22元即市低位,急挫近14%,成交增至674萬股。 和鉑醫藥-B(02142.HK)及康方生物-B(09926.HK)也兩連跌,前者股價曾考驗牛熊線(3.11元),最低見3.08元,現報3.15元,續挫逾7.4%;後者股價失守10天及20天線(48.6元及47.6元),最低見44.7元,現報45.05元,續挫7.9%。 康諾亞-B(02162.HK)、歌禮製藥-B(01672.HK)、諾誠健華-B(09969.HK)、騰盛博藥-B(02137.HK)、開拓藥業-B(09939.HK)、鷹瞳科技-B(02251.HK)及科濟藥業-B(02171.HK)跌逾4%-6%。 三大平台醫療股平安好醫生(01833.HK)、京東健康(06618.HK)及阿里健康(00241.HK)均三連跌,股價曾低見19.42元、60.55元及6.23元、現報19.6元、60.85元及6.33元,依次續跌逾4%-7%。 四大藍籌醫藥股跌逾3%-4%,其中藥明生物(02269.HK)低見60.7元,現報63.35元,續挫3.9%。此外,威高股份(01066.HK)回吐逾4%報12.96元;四環醫藥(00460.HK)回吐8.1%報1.02元,失守10天及20天線。 然而,東曜藥業-B(01875.HK)回升2.6%曾高見2.47元。半新股3D MEDICINES-B(01244.HK)反覆續升1%曾高見65.9元上市新高。此外,主要從事提供養老、醫療及健康相關之服務及產品的北京健康(02389.HK)發力追落後,股價升破牛熊線8.2仙後,升幅曾擴至1.9倍高見20.9仙,創逾3年高,現報15.2仙,仍飆升1.1倍,成交激增至2.87億股。 國資委等13部委印發《支持國有企業辦醫療機構高質量發展工作方案》提出,將國企辦醫療機構納入區域衛生規劃和醫療機構設置規劃,納入分級診療和醫療急救體系,將符合條件的國企辦醫療機構納入醫保定點範圍。同時,方案支持「以醫療健康為主業的國有企業進行重組併購」。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account